Area-level deprivation and preterm birth: results from a national, commercially-insured population.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
27 Feb 2019
Historique:
received: 24 07 2018
accepted: 12 02 2019
entrez: 1 3 2019
pubmed: 1 3 2019
medline: 11 4 2019
Statut: epublish

Résumé

Area-level deprivation is associated with multiple adverse birth outcomes. Few studies have examined the mediating pathways through which area-level deprivation affects these outcomes. The objective of this study was to investigate the association between area-level deprivation and preterm birth, and examine the mediating effects of maternal medical, behavioural, and psychosocial factors. We conducted a retrospective cohort study using national, commercial health insurance claims data from 2011, obtained from the Health Care Cost Institute. Area-level deprivation was derived from principal components methods using ZIP code-level data. Multilevel structural equation modeling was used to examine mediating effects. In total, 138,487 women with a live singleton birth residing in 14,577 ZIP codes throughout the United States were included. Overall, 5.7% of women had a preterm birth. In fully adjusted generalized estimation equation models, compared to women in the lowest quartile of area-level deprivation, odds of preterm birth increased by 9.6% among women in the second highest quartile (odds ratio (OR) 1.096; 95% confidence interval (CI) 1.021, 1.176), by 11.3% in the third highest quartile (OR 1.113; 95% CI 1.035, 1.195), and by 24.9% in the highest quartile (OR 1.249; 95% CI 1.165, 1.339). Hypertension and infection moderately mediated this association. Even among commercially-insured women, area-level deprivation was associated with increased risk of preterm birth. Similar to individual socioeconomic status, area-level deprivation does not have a threshold effect. Implementation of policies to reduce area-level deprivation, and the screening and treatment of maternal mediators may be associated with a lower risk of preterm birth.

Sections du résumé

BACKGROUND BACKGROUND
Area-level deprivation is associated with multiple adverse birth outcomes. Few studies have examined the mediating pathways through which area-level deprivation affects these outcomes. The objective of this study was to investigate the association between area-level deprivation and preterm birth, and examine the mediating effects of maternal medical, behavioural, and psychosocial factors.
METHODS METHODS
We conducted a retrospective cohort study using national, commercial health insurance claims data from 2011, obtained from the Health Care Cost Institute. Area-level deprivation was derived from principal components methods using ZIP code-level data. Multilevel structural equation modeling was used to examine mediating effects.
RESULTS RESULTS
In total, 138,487 women with a live singleton birth residing in 14,577 ZIP codes throughout the United States were included. Overall, 5.7% of women had a preterm birth. In fully adjusted generalized estimation equation models, compared to women in the lowest quartile of area-level deprivation, odds of preterm birth increased by 9.6% among women in the second highest quartile (odds ratio (OR) 1.096; 95% confidence interval (CI) 1.021, 1.176), by 11.3% in the third highest quartile (OR 1.113; 95% CI 1.035, 1.195), and by 24.9% in the highest quartile (OR 1.249; 95% CI 1.165, 1.339). Hypertension and infection moderately mediated this association.
CONCLUSIONS CONCLUSIONS
Even among commercially-insured women, area-level deprivation was associated with increased risk of preterm birth. Similar to individual socioeconomic status, area-level deprivation does not have a threshold effect. Implementation of policies to reduce area-level deprivation, and the screening and treatment of maternal mediators may be associated with a lower risk of preterm birth.

Identifiants

pubmed: 30813938
doi: 10.1186/s12889-019-6533-7
pii: 10.1186/s12889-019-6533-7
pmc: PMC6391769
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

236

Subventions

Organisme : AHRQ HHS
ID : T32 HS017589
Pays : United States
Organisme : AHRQ HHS
ID : T32 HS022242
Pays : United States
Organisme : NIH HHS
ID : 5T32HS017589-10
Pays : United States
Organisme : HRSA HHS
ID : R40MC28308
Pays : United States

Références

Soc Sci Med. 2017 Feb;175:143-151
pubmed: 28088620
MMWR Surveill Summ. 2015 Jun 19;64(4):1-19
pubmed: 26086743
Acta Obstet Gynecol Scand. 2014 Aug;93(8):727-40
pubmed: 24834960
Paediatr Perinat Epidemiol. 2000 Jul;14(3):194-210
pubmed: 10949211
Ann Epidemiol. 2010 Jun;20(6):445-51
pubmed: 20470971
Lancet Diabetes Endocrinol. 2016 Jun;4(6):517-24
pubmed: 27131930
Soc Sci Med. 2009 Jan;68(1):100-10
pubmed: 18995941
J Epidemiol Community Health. 2003 Mar;57(3):186-99
pubmed: 12594195
Obstet Gynecol. 2017 Feb;129(2):285-294
pubmed: 28079772
Int J Health Geogr. 2004 Oct 12;3(1):22
pubmed: 15479473
J Urban Health. 2006 Mar;83(2):162-75
pubmed: 16736366
Health Aff (Millwood). 2015 Jul;34(7):1212-9
pubmed: 26153317
J Urban Health. 2006 Nov;83(6):1041-62
pubmed: 17031568
Womens Health Issues. 2017 Sep - Oct;27(5):551-558
pubmed: 28420558
Ann N Y Acad Sci. 2010 Feb;1186:5-23
pubmed: 20201865
Med Care. 2019 Feb;57(2):109-114
pubmed: 30570588
Paediatr Perinat Epidemiol. 2009 Jan;23(1):87-96
pubmed: 19228318
Am J Epidemiol. 2008 Jan 15;167(2):155-63
pubmed: 17989062
Lancet. 2015 Dec 12;386(10011):2442-4
pubmed: 26364261
Natl Vital Stat Rep. 2015 Aug 6;64(9):1-30
pubmed: 26270610
Paediatr Perinat Epidemiol. 2006 May;20(3):188-200
pubmed: 16629693
J Expo Sci Environ Epidemiol. 2012 Sep;22(5):429-38
pubmed: 22617723
Soc Sci Med. 2012 Apr;74(8):1204-12
pubmed: 22365939
Int J Health Geogr. 2010 Jul 05;9:35
pubmed: 20602784
Psychol Methods. 2010 Sep;15(3):209-33
pubmed: 20822249
Ann Epidemiol. 2015 Feb;25(2):120-5
pubmed: 25523896
N Engl J Med. 2016 Jan 14;374(2):194-6
pubmed: 26760102
Natl Vital Stat Rep. 2018 Nov;67(8):1-50
pubmed: 30707672
Int J Environ Res Public Health. 2013 Jun 05;10(6):2296-335
pubmed: 23739649
J Urban Health. 2013 Oct;90(5):857-71
pubmed: 22907713
Health Place. 2014 Nov;30:98-106
pubmed: 25240489
Int J Health Geogr. 2013 Jun 20;12:32
pubmed: 23786633
J Community Health. 2003 Oct;28(5):335-46
pubmed: 14535599
Am J Epidemiol. 2011 Sep 15;174(6):744-52
pubmed: 21771918
Am J Obstet Gynecol. 2005 Jul;193(1):125-34
pubmed: 16021070
Am J Public Health. 2002 Jul;92(7):1100-2
pubmed: 12084688
Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):7-15
pubmed: 22753079
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Natl Vital Stat Rep. 2015 Dec;64(12):1-64
pubmed: 26727629
JAMA. 2018 Feb 13;319(6):579-587
pubmed: 29450525
Am J Obstet Gynecol. 2005 May;192(5 Suppl):S22-9
pubmed: 15891708

Auteurs

Renee Mehra (R)

Yale School of Public Health, PO Box 208034, New Haven, CT, 06520-8034, USA. renee.mehra@yale.edu.

Fatma M Shebl (FM)

Yale School of Public Health, PO Box 208034, New Haven, CT, 06520-8034, USA.
Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Boston, MA, 02114, USA.

Shayna D Cunningham (SD)

Yale School of Public Health, PO Box 208034, New Haven, CT, 06520-8034, USA.

Urania Magriples (U)

Department of Obstetrics, Gynecology and Reproductive Sciences, Yale School of Medicine, PO Box 208063, New Haven, CT, 06520, USA.

Eric Barrette (E)

Health Care Cost Institute, 1100 G Street NW, Suite 600, Washington, DC, 20005, USA.
Medtronic, 950 F Street NW, Suite 500, Washington, DC, 20004, USA.

Carolina Herrera (C)

Boston University School of Public Health, 715 Albany Street, Boston, MA, 02118, USA.

Katy B Kozhimannil (KB)

Division of Health Policy and Management, University of Minnesota School of Public Health, 420 Delaware Street SE, Minneapolis, MN, 55455, USA.

Jeannette R Ickovics (JR)

Yale School of Public Health, PO Box 208034, New Haven, CT, 06520-8034, USA.
Yale-NUS College, 20 College Avenue West #03-401, Singapore, 138529, Singapore.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH